Free Trial
NASDAQ:DVAX

Dynavax Technologies (DVAX) Stock Price, News & Analysis

Dynavax Technologies logo
$10.27 +0.01 (+0.10%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$10.30 +0.04 (+0.34%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dynavax Technologies Stock (NASDAQ:DVAX)

Key Stats

Today's Range
$10.18
$10.36
50-Day Range
$9.77
$11.36
52-Week Range
$9.22
$14.63
Volume
1.92 million shs
Average Volume
1.84 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.33
Consensus Rating
Moderate Buy

Company Overview

Dynavax Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

DVAX MarketRank™: 

Dynavax Technologies scored higher than 93% of companies evaluated by MarketBeat, and ranked 77th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Dynavax Technologies has only been the subject of 1 research reports in the past 90 days.

  • Read more about Dynavax Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dynavax Technologies is -22.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dynavax Technologies is -22.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dynavax Technologies has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dynavax Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    12.97% of the float of Dynavax Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Dynavax Technologies has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Dynavax Technologies has recently decreased by 4.42%, indicating that investor sentiment is improving.
  • Dividend Yield

    Dynavax Technologies does not currently pay a dividend.

  • Dividend Growth

    Dynavax Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.97% of the float of Dynavax Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Dynavax Technologies has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Dynavax Technologies has recently decreased by 4.42%, indicating that investor sentiment is improving.
  • News Sentiment

    Dynavax Technologies has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Dynavax Technologies this week, compared to 6 articles on an average week.
  • Search Interest

    1 people have searched for DVAX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dynavax Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $41,116.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.98% of the stock of Dynavax Technologies is held by insiders.

  • Percentage Held by Institutions

    96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dynavax Technologies' insider trading history.
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DVAX Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
See More Headlines

DVAX Stock Analysis - Frequently Asked Questions

Dynavax Technologies' stock was trading at $12.77 on January 1st, 2025. Since then, DVAX shares have decreased by 19.6% and is now trading at $10.27.

Dynavax Technologies Corporation (NASDAQ:DVAX) posted its earnings results on Thursday, August, 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. The biopharmaceutical company had revenue of $95.44 million for the quarter, compared to analysts' expectations of $87.55 million. Dynavax Technologies had a positive trailing twelve-month return on equity of 5.10% and a negative net margin of 16.67%.
Read the conference call transcript
.

Dynavax Technologies' top institutional shareholders include State Street Corp (5.45%), Chicago Capital LLC (4.35%), Geode Capital Management LLC (2.24%) and Blair William & Co. IL (1.90%). Insiders that own company stock include Andrew A F Hack, Robert Janssen, Francis Cano, Scott Dunseth Myers, David F Novack and Justin Burgess.
View institutional ownership trends
.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/07/2025
Today
8/29/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DVAX
CIK
1029142
Employees
350
Year Founded
1996

Price Target and Rating

High Price Target
$32.00
Low Price Target
$10.00
Potential Upside/Downside
+136.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
32.09
P/E Growth
N/A
Net Income
$27.31 million
Net Margins
-16.67%
Pretax Margin
-15.56%
Return on Equity
5.10%
Return on Assets
3.00%

Debt

Debt-to-Equity Ratio
0.45
Current Ratio
6.65
Quick Ratio
6.01

Sales & Book Value

Annual Sales
$277.25 million
Price / Sales
4.34
Cash Flow
$0.16 per share
Price / Cash Flow
64.79
Book Value
$4.21 per share
Price / Book
2.44

Miscellaneous

Outstanding Shares
117,270,000
Free Float
113,772,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
1.09

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:DVAX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners